CN103191189B - Five-ingredient botanical composition for treating hepatic fibrosis and preparation method thereof - Google Patents
Five-ingredient botanical composition for treating hepatic fibrosis and preparation method thereof Download PDFInfo
- Publication number
- CN103191189B CN103191189B CN201310111279.6A CN201310111279A CN103191189B CN 103191189 B CN103191189 B CN 103191189B CN 201310111279 A CN201310111279 A CN 201310111279A CN 103191189 B CN103191189 B CN 103191189B
- Authority
- CN
- China
- Prior art keywords
- cordyceps
- ethanol
- herb gynostemmae
- gynostemmae pentaphylli
- polysaccharides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a five-ingredient botanical composition for treating hepatic fibrosis and a preparation method thereof. In every kilogram by weight, the composition contains the following ingredients: 180-350 mg of crude cordyceps polysaccharide, 0.06-0.82 ml of fat-soluble cordyceps ingredient, 100-190 mg of salvianolic acid, 2-68 mg of gynostemma pentaphyllum saponin and 3-12 mg of gynostemma pentaphyllum polysaccharide. The method comprises the following steps of: (1) extracting the crude cordyceps polysaccharide, the fat-soluble cordyceps ingredient, the salvianolic acid, the gynostemma pentaphyllum saponin and the gynostemma pentaphyllum polysaccharide; and (2) preparing original ingredient liquid and various clinical preparations according to combination doses. The composition has the same role as that of a composition of cordyceps mycelia, peach kernel and gynostemma pentaphyllum and can obviously improve the treatment effect and reduce side effects, thereby having good clinical application prospects.
Description
Technical field
The invention belongs to plant amedica components composition for the treatment of hepatic fibrosis and preparation method thereof, particularly a kind of 5 component botanical drug compositions for the treatment of hepatic fibrosis and preparation method thereof.
Background technology
China is the hotspot of the hepatic disease such as chronic viral hepatitis B in the world, and the health of chronic hepatopathy to our people causes significant damage for a long time.But, up till now treating liver fibrosis or chronic hepatopathy treatment in a large difficult point.From the eighties in last century, Shanghai Univ. of Traditional Chinese Medicine successfully formulates anti-hepatic fibrosis country new Chinese medicine " FUZHENG HUAYU JIAONANG " (the accurate word 20020073 of traditional Chinese medicines), this medicine is made up of Radix Salviae Miltiorrhizae, Cordyceps mycelium, Semen Persicae, Herb Gynostemmae Pentaphylli, Pollen Pini, Fructus Schisandrae Chinensis, and effect is blood circulation promoting and blood stasis dispelling, beneficial smart tonify deficiency.Research for many years confirms that FUZHENG HUAYU JIAONANG effectively can improve chronic hepatitis Bhepatic fibrosis, liver tissue fibrosis reversion rate by stages (more than comparatively decline before treatment 1 phase or 1 phase) reaches 52%, by the clinical observation of 2 years by a definite date, show the upper gastrointestinal hemorrhage rate that this medicine can reduce Cirrhotic Patients.
But the preparation of FUZHENG HUAYU JIAONANG is relatively backward at present, and 5 capsules of once taking medicine, cause some patients gastrointestinal reaction, although the tablet developed can reduce stomach discomfort, but still there is the demand improving treatment hepatic fibrosis clinical efficacy further." pharmacology " records, and the amygdaloside in Semen Persicae can produce a large amount of hydrocyanic acids after intestinal digestive enzyme decomposes, and occurs hydrocyanism.Although never there is patient clinically to occur poisoning event because taking supporting vital QI and dispersing blood stasis compound recipe, how to prevent potential serious toxic and side effects very necessary.Therefore, further secondary development supporting vital QI and dispersing blood stasis Chinese medicine compound, curative effect is improved again in the basis of existing reverse hepatic fibrosis 52%, and reducing toxic and side effects is the direction that efforts still need to be.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of 5 component botanical drug compositions for the treatment of hepatic fibrosis and preparation method thereof, can significantly improve curative effect, reduces side effect, has good potential applicability in clinical practice.
A kind of 5 component botanical drug compositions for the treatment of hepatic fibrosis of the present invention, raw material is made up of Cordyceps mycelium, Radix Salviae Miltiorrhizae and Herb Gynostemmae Pentaphylli.
The compatibility dosage of described 5 component stock solutions, is respectively by per kilogram of body weight: Cordyceps crude polysaccharides 180-350mg, Cordyceps fat-soluble ingredient 0.06 ~ 0.82ml, salvianolic acid 100-190mg, gypenoside 2-68mg, Herb Gynostemmae Pentaphylli polysaccharides 3-12mg.
Preferably be respectively by per kilogram of body weight: Cordyceps crude polysaccharides 230 ~ 250mg, Cordyceps fat-soluble ingredient 0.1 ~ 0.2ml, salvianolic acid 120 ~ 140mg, gypenoside 10 ~ 30mg, Herb Gynostemmae Pentaphylli polysaccharides 7 ~ 8mg.
Preferably further to be respectively by per kilogram of body weight: Cordyceps crude polysaccharides 240mg, Cordyceps fat-soluble ingredient 0.1ml, salvianolic acid 130mg, gypenoside 20mg, Herb Gynostemmae Pentaphylli polysaccharides 7.3mg.
A kind of preparation method for the treatment of 5 component botanical drug compositions of hepatic fibrosis in the present invention, comprising:
(1) 5 components described in extraction: Cordyceps crude polysaccharides, Cordyceps fat-soluble ingredient, salvianolic acid, gypenoside and Herb Gynostemmae Pentaphylli polysaccharides;
1. Cordyceps fat-soluble ingredient: get Cordyceps mycelium powder, put into the extraction kettle of supercritical extraction instrument after granulating with 20% ethanol water, extraction conditions: temperature is 45 DEG C, pressure is 30MPa, and the time is 2h, and flow is 35kg/h.Separation condition is: first order separating pressure is 10MPa, and temperature is 50 DEG C, and second level separating pressure is 6MPa, and temperature is 40 DEG C.Collect the grease being separated and parsing, obtain Cordyceps fat-soluble ingredient.
2. Cordyceps crude polysaccharides: the Cordyceps mycelium slag after supercritical extraction is boiled 3 hours in 10 times of NaOH aqueous solutions of pH=8, totally 2 times, after merging, centrifugally to remove slag, supernatant concentration, adding ethanol to final concentration is 75%, and refrigerator is placed, separate out polysaccharide, filter, clean dry
3. salvianolic acid: get red rooted salvia 1kg, adds 10 times amount deionized waters, boils 1h, inclined to by medicinal liquid.Add 10 times amount deionized waters in medicinal residues again, boil 1h, medicinal liquid is inclined to.Merge extracted twice liquid, leave standstill, filter.Be concentrated into 1.5L, medicinal liquid compares for 1:1.5(proportion is 1.11), add 4.2L95% ethanol to concentration of alcohol and be about 70%, precipitate with ethanol spends the night.Centrifugal, upper solution decompression is concentrated into without alcohol taste, about 1.5L.Get the HZ-816 resin 2L that pretreatment is good, wet method dress post, with deionized water rinsing extremely without alcohol taste, with the flow velocity of 1/2 bed volume/hour (BV/h) by after said extracted concentrated solution upper prop, then with the ethanol elution salvianolic acid of 2.5BV40%, flow velocity is 1BV/h.Collect 40% ethanol elution, drying under reduced pressure, obtain yellow solid powder.After measured, the yield of salvianolic acid component is about 8%, and wherein the content of the phenolic acid such as salvianolic acid B is about 25%.
4. gypenoside: take Gynostemma pentaphyllum 1kg, adds 60% ethanol of 20 times amount, reflux, extract, 2h, filters.Filtrate reduced in volume is to extractum shape.Add 30% ethanol to solid-liquid ratio 1:3, ultrasonic dissolution 15min, centrifugal, supernatant crosses macroporous adsorbent resin.Get the HZ-816 resin 2L that pretreatment is good, wet method dress post, with deionized water rinsing extremely without alcohol taste.By Herb Gynostemmae Pentaphylli extract with 1/4BV/h flow velocity upper prop, rinse with 1/2BV/h flow velocity 2BV water, discard leacheate.Again under identical flow velocity, with 2BV30% alcohol flushing, discard leacheate.Last with 3BV95% ethanol elution gypenoside, collect 95% ethanol elution, concentrating under reduced pressure, drying, obtain faint yellow solid powder.After measured, the yield of gypenoside class component is about 1%, and wherein Herb Gynostemmae Pentaphylli total glycosides content is about 40%.
5. Herb Gynostemmae Pentaphylli polysaccharides: will 4. in extraction process Herb Gynostemmae Pentaphylli medicinal residues naturally dry.Take medicinal residues 500g, with 15 times amount deionized water reflux, extract, 1h, filter.Filtrate reduced in volume is to solid-liquid ratio 1:1.Add the ethanol 900ml of 95%, to alcohol content about 70%, precipitate with ethanol spends the night.Filter, filter cake 95% ethanol twice, dry, pulverize.Obtain yellow Herb Gynostemmae Pentaphylli polysaccharides powder.After measured, the yield of Herb Gynostemmae Pentaphylli soap polysaccharide component is about 4%, and wherein Herb Gynostemmae Pentaphylli polysaccharides content is about 15%.
(2) by compatibility dosage, component stock solution is made.
Described component stock solution is applied to the preparation of the specific part slow release of intestinal, and consumption, according to age of route of administration, patient, body weight, the adjustment such as type and the order of severity of disease for the treatment of, can be used by one or many.
Described plant amedica compositions can be made into solid preparation, as tablet or capsule.
Described plant amedica compositions can be made into microcapsule.
Through experiment for many years and clinical research, the mechanism of action of FUZHENG HUAYU JIAONANG anti-hepatic fibrosis and material base are clearer and more definite.Amygdaloside in component, the Semen Persicaes such as the Cordyceps polysaccharide in research discovery Cordyceps mycelium and the salviol acid A in Radix Salviae Miltiorrhizae, B have remarkable effect of anti hepatic fibrosis.As Cordyceps polysaccharide can promote I, III Collagen Type VI degraded, obviously reduce the content of fibrosis rat liver tissue TGF-β 1 and TBRI thereof; Amygdaloside in Semen Persicae significantly can suppress the propagation of HSC and the anabolism of collagen stroma composition, promotes its catabolism; Salvianolic acid B has significant anti-carbon tetrachloride (CCl
4) and N-nitrosodimethylamine (DMN) the rat liver fibrosis effect of inducing, suppress go down to posterity hepatic stellate cell (HSC) propagation and collagenation, suppress the HSC intracellular signal transduction of TGF-β 1, thus reduce the total amount of the HSC secretion TGF-B1 that goes down to posterity and suppress it to activate.And salviol acid A suppresses collage synthesis by significant anti peroxidation of lipid damaging action.Once Effect of Fuzheng Huayu Recipe in Treating CCl was used
4the in type rat liver fibrosis of induction, finds that each herbal medicine in Fuzheng Huayu Recipe mainly contains following characteristics: the 1) principal agent of collagen fiber degraded in anti-hepatic fibrosis, promotion liver in the Semen Persicae side of being; 2) Radix Salviae Miltiorrhizae is to improving liver function, and short albumin synthesis and reduction serum bilirubin level play a major role; 3) Cordyceps mycelium is the factor of influence reducing serum total bilirubin content; 4) Herb Gynostemmae Pentaphylli is that the party protects hepatocyte, reduces the principal agent of serum ALT activities.
Because the amygdaloside in Semen Persicae has potential serious toxic and side effects, and the medicine that Pollen Pini in the former side of supporting vital QI and dispersing blood stasis and Fructus Schisandrae Chinensis not play a major role, so the present invention picks in Fuzheng Huayu Recipe the Cordyceps with " righting " effect, there is the Radix Salviae Miltiorrhizae of " blood circulation promoting and blood stasis dispelling " effect and there are the 3 taste Chinese medicines such as Herb Gynostemmae Pentaphylli that " heat-clearing and toxic substances removing " act on.Therefrom extract and purification 5 kinds of active components: salvianolic acid (Radix Salviae Miltiorrhizae), gypenoside, Herb Gynostemmae Pentaphylli polysaccharides (Herb Gynostemmae Pentaphylli), Cordyceps crude polysaccharides, Cordyceps mycelium CO
2supercritical extract (Cordyceps mycelium).Adopt the method for uniform Design, screen, and analyze by NONMEN method these 5 kinds of extraction components, the optimum compatibility dosage of active component group filtering out Fuzheng Huayu Recipe is: Cordyceps crude polysaccharides (240mgkg
-1), Cordyceps fat-soluble ingredient (0.1mlkg
-1), Herb Gynostemmae Pentaphylli polysaccharides (7.3mgkg
-1), gypenoside (20mgkg
-1), salvianolic acid (130mgkg
-1).
beneficial effect
Plant amedica 5 combination of components raw material of the present invention is made up of Cordyceps mycelium, Radix Salviae Miltiorrhizae and Herb Gynostemmae Pentaphylli.It is identical that its effect and Cordyceps mycelium, Semen Persicae and Herb Gynostemmae Pentaphylli form, there is through zoopery the antifibrosis therapy effect of anti-hepatic fibrosis and other organs, the more former compound plant medicine of curative effect has the trend of potentiation, be conducive to Clinical pharmacokinetics and pharmacological research, have a good application prospect.
Accompanying drawing explanation
In the following drawings, A group is supporting vital QI and dispersing blood stasis former side's extractum group; D group is the present invention;
Fig. 1 is normal group, model group, A group and D group rat liver HE colored graph (× 200);
Fig. 2 is normal group, model group, A group and D group rat liver sirius red colored graph (× 100);
Fig. 3 is normal group, model group, A group and D group rat liver collagen deposition area change;
Fig. 4 is the changes of contents of normal group, model group, A group and D group liver tissues of rats Hyp;
Fig. 5 is that normal group, model group, A group and D group rat blood serum ALT are active;
Fig. 6 is that normal group, model group, A group and D group rat blood serum AST are active;
Fig. 7 is normal group, model group, A group and D group rat blood serum Alb content;
Fig. 8 is normal group, model group, A group and D group rat blood serum TBiL content.
Detailed description of the invention
Below in conjunction with specific embodiment, set forth the present invention further.Should be understood that these embodiments are only not used in for illustration of the present invention to limit the scope of the invention.In addition should be understood that those skilled in the art can make various changes or modifications the present invention, and these equivalent form of values fall within the application's appended claims limited range equally after the content of having read the present invention's instruction.
Embodiment 1
The anti-hepatic fibrosis curative effect of supporting vital QI and dispersing blood stasis compound recipe active component compound recipe:
1.1 animals:
Wistar male rat 59, SPF level, body weight 150 ± 10g, Chinese Academy of Sciences's Shanghai Experimental Animal Center provides, and credit number: SCXK (Shanghai): 2007-0005.All rat feedings are in Shanghai Univ. of Traditional Chinese Medicine Experimental Animal Center SPF laboratory, and full diet, freely drinks water.
1.2 main agents:
N-nitrosodimethylamine (dimethylnitrosamine, DMN), purchased from Tokyo HuaCheng Industry Co., Ltd, lot number: MAL05; Citric acid, analytical pure, lot number: F20080916; Anhydrous sodium acetate, analytical pure, lot number: F20080714; Trisodium citrate (Tri-sodium citrate), analytical pure, lot number: F20070110; Paradimethylaminobenzaldehyde (4-Dimethylaminobenzaldehyde), lot number: F20090516; Chlorine ammonia-T (chloramines-T), analytical pure, lot number: T20061130; Dehydrated alcohol, analytical pure, lot number: 20090716; Dimethylbenzene, analytical pure, lot number 20100123; Formaldehyde (Formal dehyde solution), lot number: 20071019; Isopropyl alcohol (Iso-propanol), analytical pure, lot number: T20070815; Concentrated hydrochloric acid, analytical pure, lot number: T20090312, above all purchased from Solution on Chemical Reagents in Shanghai company of Chinese Medicine group.Neutral gum, lot number: 60090715, purchased from Shanghai Yi Yang Instrument Ltd..0.9% sodium chloride injection (Sodium Chloride Injection), lot number: 090903, purchased from Shuanghe Pharmaceutical Ind Co., Ltd., Anhui.Pentobarbital sodium (Pentobarbital Sodium, Lot.No.WS20090920, German subpackage.Hydroxyproline (hydroxyproline, Hyp) standard substance, analytical pure, Sigma-Aldrich Chemie GmbH, Germany product.Perchloric acid (Perchloric acid), analytical pure, lot number: 20070807 purchased from Tao Pu chemical plant, Shanghai.Serum liver functional reagent box, comprise glutamate pyruvate transaminase (alanine aminotransamine, ALT), glutamic oxaloacetic transaminase, GOT (aspartateaminotransferase, AST), albumin (albumin, Alb), total bilirubin (total bilirubin, T.Bil), all Bioengineering Research Institute is built up purchased from Nanjing.
1.3 medicines:
Cordyceps crude polysaccharides, Cordyceps fat-soluble ingredient, salvianolic acid, gypenoside, the same Part I of Herb Gynostemmae Pentaphylli polysaccharides.The extract dry powder of supporting vital QI and dispersing blood stasis compound recipe is provided by Shanghai Modern TCM Co., Ltd., lot number: 100306, main quality control index (HPLC mensuration): danshensu sodium 10.48mg/g; Adenosine 2.5mg/g; Salvianolic acid B 12.4mg/g; Moisture content: 6.9%.During application, dilution is the solution gavage liquid of 94.5mg/ml.
1.4 key instruments:
FIM20 ice machine, Dutch Phillips product.The biochemical special refrigerator of upper Pedicellus et Pericarpium Trapae, purchased from upper marine Pedicellus et Pericarpium Trapae company.Cryogenic refrigerator (-70 DEG C), Forma scientific Products.Desk centrifuge (microfuge lite), Beckman Products.AA-200 analytical balance, Denver instrument company of inverted microscope (37 × B) U.S. product.Pure water system (HPLC/UP), Labconco Products.CQX25-12 ultrasonic cleaner, Shanghai must ultrasonic company limited product.Rotary microtome (RM2035), HI1220 bake sheet machine, HI1210 thermostat water bath, and LEICA ASP300 automatic dehydrator, LEICA EG1160 paraffin wax embedding, all purchased from German Leica company.Instant camera, Polariod Products.XW-80A type vortex mixer, its woods Bel instrument manufacturing company limited of Haimen, Jiangsu.ML-902 time constant-temperature magnetic stirring apparatus, Shanghai Pujiang analytical tool factory produces.PH meter (
), Beckmanwc Products.1000 μ l, 200 μ l, 20 μ l sample injectors, French Gilson company manufactures.The multi-functional microplate reader of M5, Molecular Devices company of the U.S. produces.Precellys24 homogenizer, French Bertin company produces.
2.1 model preparations
Wistar male rat 59, after conforming 3 days, is divided into normal group (10) and modeling group (49) at random by the method for table of random number.Modeling group 0.5%DMN presses 2mlkg
-1body weight lumbar injection, injects 2/3 of full dosage first, every day 1 time, continuously rest 4d after injection 3d, totally 3 weeks, within first 3 days of the 4th week, injects 0.5%DMN full dose, 2/3 amount and 1/2 amount respectively.Normal rats gives the sodium chloride injection of identical time and position lumbar injection equivalent.
2.2 administration
Modeling the 4th week, get 3 rats at random and put to death observation hepatic lesions situation, after confirming have hepatic fibrosis to change, the method for remaining 46 rat table of random numbers is divided into 1 model group (18) and 2 treatment groups (A, D), A is supporting vital QI and dispersing blood stasis former side's extractum group; D is the present invention, often organizes 14.D treatment group prepares dosage according to table 1, with 5mlkg with each group of corresponding component aqueous solution respectively
-1body weight gavage.Cordyceps fat-soluble ingredient is due to can not be soluble in water very well, and every 100g rat body weight expense is very little, so press 0.5mlkg with after edible oil dilution
-1the other gavage of body weight.A group administration supporting vital QI and dispersing blood stasis extractum, dosage 5mlkg
-1body weight, normal group and model group isodose drinking water and edible oil gavage, totally 4 weeks every day 1 time.
Table 1 Chinese drug-treated group grouping gavage component extract compatibility dosage
2.3 sample reception
Experiment terminates rear Rat Fast and can't help water, takes rat body weight, with 3% pentobarbital sodium 2mlkg after 24h
-1the dosage lumbar injection of body weight, postanesthetic rat opens abdominal cavity completely, if any ascites, takes ascites weight after blotting liquid to claim overweight dry cotton ball.Then take a blood sample through postcava with 10ml syringe, leave standstill after 2 hours at 4 DEG C, 3000rpm, 15min are centrifugal, get supernatant and are sub-packed in 1.5ml centrifuge tube ,-70 DEG C of cryopreservation.Animal is got after blood puts to death, and takes off liver and spleen claims its weight record, then gets about 1.0cm × 0.8cm × 0.3cm size hepatic tissue 2 pieces, fixing in 10% neutral buffered formalin.
2.4 Serum bichemisbry detect
ALT activity adopts reitman-frankel method; AST activity adopts reitman-frankel method; Alb content adopts Bromocresol green; TBiL content adopts sodium benzoate-caffeine colorimetry.
2.5 hepatic tissue hydroxyproline (Hydroxyproline, Hyp) assays
JamallShi method is adopted to measure
2.6 liver histologicals are observed
2.6.1 dyeing
The hepatic tissue that formaldehyde is fixing, dehydration of alcohol step by step after 24h, dimethylbenzene is transparent, 56 DEG C of paraffin embedding, 4 μm of thick sections, for HE, sirius red dyeing, om observation.
2.6.2 hepatic tissue hemorrhagic necrosis grading standard
The hepatic injury of the rat model of DMN induction, based on hemorrhagic necrosis.Make standard by oneself, under light microscopic (200 ×), observe classification.(see table 2)
Table 2 hepatic tissue hemorrhagic necrosis grading
2.6.3 the semi-quantitative standards of hepatic tissue Collagen fiber deposition degree
According to the semi-quantitative standards of pertinent literature, observe hepatic fibrosis degree.
Table 3 hepatic tissue Collagen fiber deposition degree by stages
2.6.4 hepatic tissue Collagen fiber deposition area image procossing semi-quantitative analysis
Often open sirius red staining section and get corner and central authorities' totally 5 position pictures taken respectively, adopt image-pro plus6.1 computed in software to go out every pictures collagen deposition area, average.
2.7 statistical method
SPSS 18.0 software statistics system is adopted to carry out statistical disposition.Measurement data with
represent, adopt ANOVA program to carry out one factor analysis of variance, carry out homogeneity test of variance, and compare between two by LSD program; Ranked data Ridit method is checked.(with α=0.05 for notable level carries out statistical test).
3 results
3.1 rat ordinary circumstances
Each group of rat modeling situation: modeling at the end of 4 weeks without rats death.At the end of experiment in 8 weeks, normal rats is without death, dead 2 of model group, dead 2 of A group, dead 1 of D group, and time dead, the rat mental status is very poor, and weight loss is obvious, and feed reduces, and may be that liver failure is dead.Find that model group 11 rats have ascites at the end of experiment in 8 weeks, AS occurrence is the AS occurrence of 68.8%, D group is 69.2%.(see table 4)
A situation arises for table 4 each group rats death and ascites
3.2 respectively organize rat body weight, liver body ratio, spleen body comparatively frequently
Compare with normal group, model group rats body weight significantly reduces, and spleen is heavy obviously to be increased, and spleen body is than increasing; Compare with model group, each group rat body weight all has reply, and wherein the amplitude of A group is comparatively large, has significant difference.All the other each index changes no significant difference between A, D group and model group.(see table 5)
The comparison of rats'liver weight, spleen weight, liver body ratio, spleen body ratio respectively organized by table 5
| Grouping | N | Body weight (g) | Liver heavy (g) | Spleen heavy (g) | Liver body ratio | Spleen body ratio |
| Normal group | 10 | 324±23.3 | 8.95±1.02 | 0.71±0.074 | 0.028±0.0019 | 0.0022±0.0003 |
| Model group | 16 | 256±43.9 ## | 7.54±1.96 | 1.44±0.263 # | 0.029±0.0040 | 0.0059±0.0017 # |
| A group | 12 | 290±36.9 * | 8.56±2.01 | 1.34±0.278 | 0.029±0.0043 | 0.0047±0.0011 |
| D group | 13 | 268±52.8 | 7.92±2.26 | 1.40±0.037 | 0.029±0.0033 | 0.0054±0.0014 |
Compare with normal group:
#p < 0.05,
##p < 0.01; Compare with model group:
*p < 0.05
3.3 rat liver pathological observations
3.3.1 gross examination of skeletal muscle
Normal rats liver color is scarlet, and matter is tender soft, smooth surface, clear-cut margin; Spleen color is dark red, and matter is medium.Model group rats Liver on Judge Hardness is comparatively hard, and color is dark red, and edge is blunt, rough surface, and liver volume obviously reduces compared with normal group, and spleen obviously increases.Treat each group of liver size compared with model group, color and luster and quality to be all improved, spleen has reducing in various degree.
3.3.2 hepatic tissue HE dyes and observes
Normal rats lobules of liver clear in structure, hepatocyte is radially arranged to surrounding along liver rope by central vein, and without degeneration necrosis, sinus hepaticus has no narrow and expansion.Compared with normal group, model group normal configuration is destroyed, and portal area spoke gathers; Hepatocyte arrangement disorder, although hepatocellular degeneration is not serious, has 5 examples to have obvious hemorrhagic necrosis to accompany inflammatory cell infiltration, has the 2 routine gallbladders that obviously become silted up in addition; Sinus hepaticus is narrow.Above-mentioned various pathological change also has existence in each treatment group, but has alleviating in various degree compared with model group.Compare between each treatment group, A group sinus hepaticus is narrow, hepatocellular degeneration degree of necrosis is lighter.(see Fig. 1, table 6)
Table 6 is group liver tissues of rats hemorrhagic necrosis grading respectively
3.3.3 the dyeing of hepatic tissue sirius red is observed
Observed result shows, and normal rats liver only has a small amount of Collagen fiber deposition around portal area and central vein.Model group rats portal area expands Liver Collagen fiber laydown, and fibrous septum is obviously formed, and part holds formation pseudolobuli.Compared with model group, each treatment group collagen fiber hyperplasia, deposition degree obviously alleviate.(see figure 2)
3.4 respectively organize rat liver collagen deposition semi-quantitative analysis
Each group of rat liver fibrosis by standard sxemiquantitative classification, and carries out analysis display with Ridit, and compared with normal group, model group significance (P < 0.01), respectively organizes no significant difference.In treatment group, no significant difference compared with model group.(see table 7)
Table 7 respectively group rat liver collagen deposition sxemiquantitative Ridit is analyzed
Compare with normal group:
##p < 0.01.
3.5 rat liver collagen deposition area image procossing
Model group rats collagen deposition area has obvious increase (P < 0.01) compared with normal group, and D group has significant minimizing, has statistical significance (P < 0.01).(see table 8, Fig. 3)
Table 8 different formulations is on the impact of rat liver collagen deposition
Compare with normal group:
##p < 0.01; Compare with model group:
*p < 0.01
3.6 liver tissues of rats hydroxyproline content changes
Compared with same period normal group, the Hyp content of model group rats hepatic tissue obviously increases (P < 0.01); Compared with model group, the Hyp content of A group liver tissues of rats obviously reduces (P < 0.01).(see table 9, Fig. 4)
Table 9 component formula is on the impact of rat Hyp
Compare with normal group:
##p < 0.01; Compare with model group:
*p < 0.01.
3.7 rat liver biochemical indicators
3.7.1 component formula is on the impact of rats with liver cirrhosis Serum ALT, AST activity
Compared with same period normal group, model group rats serum ALT activities significantly raises, (P < 0.01); Each group of Drug therapy compared with model group, A group, D group rat blood serum ALT are active significantly reduces (P < 0.05, P < 0.01).(see table 10, Fig. 5).Compared with same period normal group, model group rats serum AST is active significantly to be raised, (P < 0.05); Each treatment group and the same period model group compare the impact of rat blood serum AST activity without remarkable change.(see table 10, Fig. 6)
Table 10 component formula is on the impact of Liver Function ALT, AST
Compare with normal group:
#p < 0.05;
##p < 0.01; Compare with model group:
*p < 0.05.
3.7.2 component formula is on the impact of rats with liver cirrhosis serum Alb, TBiL activity
Compared with same period normal group, model group rats serum Alb is active significantly reduces (P < 0.01); Give each group of Drug therapy with the improvement had compared with model group the same period in various degree, wherein A group has remarkable statistical significance (P < 0.01), D group on the impact of rat blood serum Alb activity without remarkable change.Compared with normal group, model group rats serum T BiL is active significantly to be raised, (P < 0.05); Give each group of Drug therapy with the improvement had compared with model group the same period in various degree, wherein A group rat blood serum TBiL activity all significantly reduces (P < 0.01), D group on the impact of rat blood serum TBiL activity without remarkable change.(see table 11, Fig. 7,8).
Table 11 component formula is on the impact of Liver Function Alb, TBiL activity
Compare with normal group:
#p < 0.05,
##p < 0.01; Compare with model group:
*p < 0.01.
Claims (7)
1. treat 5 component botanical drug compositions of hepatic fibrosis, be respectively by per kilogram of body weight: Cordyceps crude polysaccharides 180-350mg, Cordyceps fat-soluble ingredient 0.06 ~ 0.82ml, salvianolic acid 100-190mg, gypenoside 2-68mg, Herb Gynostemmae Pentaphylli polysaccharides 3-12mg; Wherein, the extracting method of each component is as follows:
1. Cordyceps fat-soluble ingredient: get Cordyceps mycelium powder, put into the extraction kettle of supercritical extraction instrument after granulating with 20% ethanol water, extraction conditions: temperature is 45 DEG C, pressure is 30MPa, and the time is 2h, and flow is 35kg/h; Separation condition is: first order separating pressure is 10MPa, and temperature is 50 DEG C, and second level separating pressure is 6MPa, and temperature is 40 DEG C, collects the grease being separated and parsing, obtains Cordyceps fat-soluble ingredient;
2. Cordyceps crude polysaccharides: the Cordyceps mycelium slag after supercritical extraction is boiled 3 hours in 10 times of NaOH aqueous solutions of pH=8, totally 2 times, after merging, centrifugally to remove slag, supernatant concentration, adding ethanol to final concentration is 75%, and refrigerator is placed, separate out polysaccharide, filter, clean dry;
3. salvianolic acid: get red rooted salvia 1kg, add 10 times amount deionized waters, boil 1h, medicinal liquid is inclined to, 10 times amount deionized waters are added again in medicinal residues, boil 1h, medicinal liquid is inclined to, merge extracted twice liquid, leave standstill, filter, be concentrated into 1.5L, medicinal liquid is than being 1:1.5, adding 4.2L 95% ethanol to concentration of alcohol is 70%, precipitate with ethanol spends the night, centrifugal, upper solution decompression is concentrated into without alcohol taste, get the HZ-816 resin 2L that pretreatment is good, wet method dress post, with deionized water rinsing extremely without alcohol taste, with 1/2 bed volume/hour flow velocity by after said extracted concentrated solution upper prop, again with the ethanol elution salvianolic acid of 2.5BV40%, collect 40% ethanol elution, drying under reduced pressure, obtain yellow solid powder, wherein the content of the phenolic acid such as salvianolic acid B is 25%,
4. gypenoside: take Gynostemma pentaphyllum 1kg, adds 60% ethanol of 20 times amount, reflux, extract, 2h, filtrate reduced in volume, to extractum shape, adds 30% ethanol to solid-liquid ratio 1:3, ultrasonic dissolution 15min, centrifugal, supernatant crosses macroporous adsorbent resin, gets the HZ-816 resin that pretreatment is good, wet method dress post, with deionized water rinsing extremely without alcohol taste, by Herb Gynostemmae Pentaphylli extract with 1/4BV/h flow velocity upper prop, rinse with 1/2BV/h flow velocity 2BV water, discard leacheate; Again under identical flow velocity, with 2BV 30% alcohol flushing, discard leacheate, last with 3BV 95% ethanol elution gypenoside, collect 95% ethanol elution, concentrating under reduced pressure, drying, obtain faint yellow solid powder, the yield of gypenoside class component is 1%, and wherein Herb Gynostemmae Pentaphylli total glycosides content is 40%;
5. Herb Gynostemmae Pentaphylli polysaccharides: 4. naturally will dry by Herb Gynostemmae Pentaphylli medicinal residues, and take medicinal residues 500g, with 15 times amount deionized water reflux, extract, 1h, filter, filtrate reduced in volume, to solid-liquid ratio 1:1, adds the ethanol 900ml of 95%, to alcohol content about 70%, precipitate with ethanol spends the night, and filters, filter cake 95% ethanol twice, dry, pulverize, obtain yellow Herb Gynostemmae Pentaphylli polysaccharides powder, wherein Herb Gynostemmae Pentaphylli polysaccharides content is 15%.
2. a kind of 5 component botanical drug compositions for the treatment of hepatic fibrosis according to claim 1, it is characterized in that: by per kilogram of body weight, described in be respectively Cordyceps crude polysaccharides 230 ~ 250mg, Cordyceps fat-soluble ingredient 0.1 ~ 0.2ml, salvianolic acid 120 ~ 140mg, gypenoside 10 ~ 30mg, Herb Gynostemmae Pentaphylli polysaccharides 7 ~ 8mg.
3. a kind of 5 component botanical drug compositions for the treatment of hepatic fibrosis according to claim 1, it is characterized in that: by per kilogram of body weight, described in be respectively Cordyceps crude polysaccharides 240mg, Cordyceps fat-soluble ingredient 0.1ml, salvianolic acid 130mg, gypenoside 20mg, Herb Gynostemmae Pentaphylli polysaccharides 7.3mg.
4. 5 component botanical drug compositions according to claim 1, is characterized in that: the preparation making the specific part being applied to intestinal.
5. 5 component botanical drug compositions according to claim 4, is characterized in that: described preparation is tablet or capsule.
6. want 5 component botanical drug compositions described in 5 according to right, it is characterized in that: microcapsule made by described capsule.
7. a preparation method for 5 component botanical drug compositions for the treatment of hepatic fibrosis as claimed in claim 1, comprising:
(1) described 5 components are extracted: Cordyceps crude polysaccharides, Cordyceps fat-soluble ingredient, salvianolic acid, gypenoside and Herb Gynostemmae Pentaphylli polysaccharides; 1. Cordyceps fat-soluble ingredient: get Cordyceps mycelium powder, put into the extraction kettle of supercritical extraction instrument after granulating with 20% ethanol water, extraction conditions: temperature is 45 DEG C, pressure is 30MPa, and the time is 2h, and flow is 35kg/h; Separation condition is: first order separating pressure is 10MPa, and temperature is 50 DEG C, and second level separating pressure is 6MPa, and temperature is 40 DEG C, collects the grease being separated and parsing, obtains Cordyceps fat-soluble ingredient;
2. Cordyceps crude polysaccharides: the Cordyceps mycelium slag after supercritical extraction is boiled 3 hours in 10 times of NaOH aqueous solutions of pH=8, totally 2 times, after merging, centrifugally to remove slag, supernatant concentration, adding ethanol to final concentration is 75%, and refrigerator is placed, separate out polysaccharide, filter, clean dry;
3. salvianolic acid: get red rooted salvia 1kg, add 10 times amount deionized waters, boil 1h, medicinal liquid is inclined to, 10 times amount deionized waters are added again in medicinal residues, boil 1h, medicinal liquid is inclined to, merge extracted twice liquid, leave standstill, filter, be concentrated into 1.5L, medicinal liquid is than being 1:1.5, adding 4.2L 95% ethanol to concentration of alcohol is 70%, precipitate with ethanol spends the night, centrifugal, upper solution decompression is concentrated into without alcohol taste, get the HZ-816 resin 2L that pretreatment is good, wet method dress post, with deionized water rinsing extremely without alcohol taste, with 1/2 bed volume/hour flow velocity by after said extracted concentrated solution upper prop, again with the ethanol elution salvianolic acid of 2.5BV40%, collect 40% ethanol elution, drying under reduced pressure, obtain yellow solid powder, wherein the content of the phenolic acid such as salvianolic acid B is 25%,
4. gypenoside: take Gynostemma pentaphyllum 1kg, adds 60% ethanol of 20 times amount, reflux, extract, 2h, filtrate reduced in volume, to extractum shape, adds 30% ethanol to solid-liquid ratio 1:3, ultrasonic dissolution 15min, centrifugal, supernatant crosses macroporous adsorbent resin, gets the HZ-816 resin that pretreatment is good, wet method dress post, with deionized water rinsing extremely without alcohol taste, by Herb Gynostemmae Pentaphylli extract with 1/4BV/h flow velocity upper prop, rinse with 1/2BV/h flow velocity 2BV water, discard leacheate; Again under identical flow velocity, with 2BV 30% alcohol flushing, discard leacheate, last with 3BV 95% ethanol elution gypenoside, collect 95% ethanol elution, concentrating under reduced pressure, drying, obtain faint yellow solid powder, the yield of gypenoside class component is 1%, and wherein Herb Gynostemmae Pentaphylli total glycosides content is 40%;
5. Herb Gynostemmae Pentaphylli polysaccharides: 4. naturally will dry by Herb Gynostemmae Pentaphylli medicinal residues, and take medicinal residues 500g, with 15 times amount deionized water reflux, extract, 1h, filter, filtrate reduced in volume, to solid-liquid ratio 1:1, adds the ethanol 900ml of 95%, to alcohol content about 70%, precipitate with ethanol spends the night, and filters, filter cake 95% ethanol twice, dry, pulverize, obtain yellow Herb Gynostemmae Pentaphylli polysaccharides powder, wherein Herb Gynostemmae Pentaphylli polysaccharides content is 15%;
(2) by compatibility dosage, component stock solution is made.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310111279.6A CN103191189B (en) | 2013-04-01 | 2013-04-01 | Five-ingredient botanical composition for treating hepatic fibrosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310111279.6A CN103191189B (en) | 2013-04-01 | 2013-04-01 | Five-ingredient botanical composition for treating hepatic fibrosis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103191189A CN103191189A (en) | 2013-07-10 |
| CN103191189B true CN103191189B (en) | 2015-02-18 |
Family
ID=48714123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310111279.6A Active CN103191189B (en) | 2013-04-01 | 2013-04-01 | Five-ingredient botanical composition for treating hepatic fibrosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103191189B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1218745C (en) * | 2002-07-12 | 2005-09-14 | 上海现代中医药技术发展有限公司 | Health food for protecting liver and adjusting blood fat and method for preparing the same |
| CN1899415B (en) * | 2006-01-12 | 2010-05-12 | 上海现代中医药技术发展有限公司 | Chinese medicine compound preparation for treating chronic hepatic disease and its preparing method |
| CN1839996A (en) * | 2006-01-12 | 2006-10-04 | 上海现代中医药技术发展有限公司 | Chinese traditional medicine compound preparation for treating chronic hepatiosis and preparation method thereof |
| CN1883582A (en) * | 2006-06-13 | 2006-12-27 | 吴方忠 | Pharmaceutical composition for treating liver disease and method for preparing same |
-
2013
- 2013-04-01 CN CN201310111279.6A patent/CN103191189B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103191189A (en) | 2013-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101744869B (en) | Compound traditional Chinese medicine extract composition for preventing and treating diabetes | |
| CN1330670C (en) | Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof | |
| CN101167863B (en) | Proprietary Chinese medicine for treating diabetes and nephrosis and preparing method thereof | |
| CN102357226A (en) | Application of Chinese herbal medicine turmeric extraction in preparation of slimming and lipid-lowering drug or drug with lipase activity inhibition effect | |
| CN101693090B (en) | Technology for preparing compound kidney inflammation tablets | |
| CN103181947B (en) | 4-component botanical medicine composition for treating liver fibrosis, and preparation method thereof | |
| CN102357142A (en) | Use of water extract or ethanol extract of Chinese herbal medicine seville orange flower in preparation of drug for losing weight and reducing blood fat or drug for inhibiting lipase activity | |
| CN102366428A (en) | Applications of extracts from Chinese herbal medicine Oroxylum indicum in preparation of slimming and lipid lowering medicine or preparation of medicine with inhibition effect on activity of lipase | |
| CN103191189B (en) | Five-ingredient botanical composition for treating hepatic fibrosis and preparation method thereof | |
| CN103191173B (en) | Five-ingredient botanical composition for treating hepatic fibrosis and preparation method thereof | |
| CN103191188B (en) | Six-ingredient botanical composition for treating hepatic fibrosis and preparation method thereof | |
| CN102366433A (en) | Application of Chinese medicinal chrysanthemum extract in preparing weight-losing and lipid-lowering medicaments or lipase activity-inhibiting medicaments | |
| CN102370763B (en) | Application of Chinese medicinal herb immature bitter orange extract in preparation of weight-reducing and lipid-lowering medicament or preparation of medicament having lipase activity suppressing effect | |
| CN102430001B (en) | Compound rose-hip flavone preparation for preventing diabetes mellitus and preparation method thereof | |
| CN102370708A (en) | Application of extracts of Chinese herbal medicine mulberry leaf in preparation of weight-losing and lipid-lowering medicines or medicines with function of inhibiting lipase activity | |
| CN103191224A (en) | Liver-protecting function of hedan preparation | |
| CN103263467A (en) | Potent medicament of brain-and-heart, preparation method and content determination | |
| CN102389444B (en) | Application of extracts of Chinese herbal medicine jasmine in preparation of weight-losing and lipid-lowering medicines or medicines with function of inhibiting lipase activity | |
| CN102357150B (en) | Application of extractive of Chinese herbal medicine medlar to prepare medicines with effects of inhibiting lipase activity | |
| CN102389512B (en) | Application of extracts of Chinese herbal medicine aloe in preparation of weight-losing and lipid-lowering medicines or medicines with function of inhibiting lipase activity | |
| CN102366429A (en) | Application of extract of Chinese herbal medicine notopterygium root in preparing medicines for reducing weight and fat or medicines having effect of inhibiting lipase activity | |
| CN102397304A (en) | Application of Chinese herbal medicine ginkgo biloba extract to preparation of medicament for reducing weight and lipid or preparation of medicament with lipase activity inhibitory action | |
| CN102362886A (en) | Use of extract of liquoric root Chinese herbal medicine in preparation of medicines for reducing weight and fat or medicines capable of inhibiting activity of lipase | |
| CN102370694A (en) | Application of Chinese herbal medicine shrubby sophora extract to preparation of weight losing and lipid lowering medicament or medicament with lipase activity suppression effect | |
| CN102357106A (en) | Application of Chinese herbal medicine campsis grandiflora extracts in preparation of weight-losing lipid-lowering medicines or medicines with lipase activity inhibition effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160411 Address after: 233608 Chengdong Economic Development Zone, Woyang County, Anhui, Bozhou Patentee after: Anhui Zhihetang Pharmacy Co., Ltd. Address before: 200050 Shanghai City Zhaofeng Plaza No. 1027 Changning District Changning Road, 33 floor Patentee before: Shanghai Modern Traditional Chinese Medicine Co., Ltd. |